Our top pick for
Homology Medicines, Inc is a biotechnology business based in the US. Homology Medicines shares (FIXX) are listed on the NASDAQ and all prices are listed in US Dollars. Homology Medicines employs 206 staff and has a trailing 12-month revenue of around USD$2.3 million.
|52-week range||USD$8.82 - USD$22.38|
|50-day moving average||USD$12.9435|
|200-day moving average||USD$11.3192|
|Wall St. target price||USD$28.44|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-2.179|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||USD$2.3 million|
|Gross profit TTM||USD$-87,732,000|
|Return on assets TTM||-28.9%|
|Return on equity TTM||-57.5%|
|Market capitalisation||USD$516 million|
TTM: trailing 12 months
There are currently 2.2 million Homology Medicines shares held short by investors – that's known as Homology Medicines's "short interest". This figure is 2.5% up from 2.2 million last month.
There are a few different ways that this level of interest in shorting Homology Medicines shares can be evaluated.
Homology Medicines's "short interest ratio" (SIR) is the quantity of Homology Medicines shares currently shorted divided by the average quantity of Homology Medicines shares traded daily (recently around 311188.02816901). Homology Medicines's SIR currently stands at 7.1. In other words for every 100,000 Homology Medicines shares traded daily on the market, roughly 7100 shares are currently held short.
However Homology Medicines's short interest can also be evaluated against the total number of Homology Medicines shares, or, against the total number of tradable Homology Medicines shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Homology Medicines's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Homology Medicines shares in existence, roughly 50 shares are currently held short) or 0.0655% of the tradable shares (for every 100,000 tradable Homology Medicines shares, roughly 66 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Homology Medicines.
Find out more about how you can short Homology Medicines stock.
We're not expecting Homology Medicines to pay a dividend over the next 12 months.
Over the last 12 months, Homology Medicines's shares have ranged in value from as little as $8.82 up to $22.38. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Homology Medicines's is -0.2717. This would suggest that Homology Medicines's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Homology Medicines has bucked the trend.
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing across a range of genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 1/2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; and HMI-202 to treat metachromatic leukodystrophy. Homology Medicines, Inc. was founded in 2015 and is based in Bedford, Massachusetts.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.